Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics ...

Wells Fargo raised the firm’s price target on Avidity Biosciences (RNA) to $75 from $70 and keeps an Overweight rating on the shares. The firm ...

Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Times ...

Avidity Biosciences (NASDAQ:RNA) stock surged 18% Wednesday after the Financial Times reported that Swiss pharmaceutical ...

If a deal is confirmed and consummated, Novartis would claim ownership of a biotech that has raised something of a stir in ...

Novartis has made a takeover approach for rare disease-focused biotech Avidity Biosciences, as Big Pharma continues to hunt ...

There is no certainty that the buyout will come to pass, according to The Financial Times, which first reported the rumors.

Swiss pharmaceutical giant Novartis is exploring a potential acquisition of U.S. biotech firm Avidity Biosciences, according ...

Del-zota is designed for patients with mutations amenable to exon 44 skipping, which is just 7% of the overall DMD patient population, Avidity believes, although the biotech states that it is "the ...

Avidity Biosciences stock has gained more than 20% in the past five days due to positive long-term data for its lead candidate, AOC 1001, in the MARINA-OLE trial in DM1 patients.

Shares of Avidity Biosciences Inc. soared 50% in their trading debut on the Nasdaq on Friday after pricing at the top of their initial public offering range, a sign of heightened interest from ...

Avidity Bioscienes (NASDAQ:RNA) quickly soared 20% after a report that Novartis (NYSE:NVS) made a takeover approach for the ...